<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bamlanivimab and etesevimab (United States: Authorization withdrawn): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bamlanivimab and etesevimab (United States: Authorization withdrawn): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Bamlanivimab and etesevimab (United States: Authorization withdrawn): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="130779" href="/d/html/130779.html" rel="external">see "Bamlanivimab and etesevimab (United States: Authorization withdrawn): Patient drug information"</a> and <a class="drug drug_general" data-topicid="130799" href="/d/html/130799.html" rel="external">see "Bamlanivimab and etesevimab (United States: Authorization withdrawn): Drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F55487515"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Bamlanivimab and Etesevimab Emergency Use Authorization and Distribution Update</span>
<span class="collapsible-date">January 2022</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA has amended the Emergency Use Authorization for bamlanivimab and etesevimab (administered together) to limit its use to when a patient is likely to have been infected with or exposed to a variant that is susceptible to this treatment.</p>
<p style="text-indent:0em;">Because data show that bamlanivimab and etesevimab is highly unlikely to be active against the Omicron variant of COVID-19, it is not authorized for use in any US states, territories, or jurisdictions at this time. Future use may be authorized in certain regions if patients are likely to be infected or exposed to a variant that is susceptible to bamlanivimab and etesevimab.</p>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Fcoronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron&amp;token=sNdy3jVSLktHVITyVxu%2BP4rXOgmfBBm6tYYIoETBRS7SVhAz0eSfA%2FyGiIxQAOgt1V%2B6G%2Ftuil3cGNmUOQOUUiklJedMocH2NREyfnckgOpYFYtr2apV1gOstq%2BunN%2BXfWcik6nKEAijPpgvrNFQWi7saGYmM8Wtjg739pxRGe8%3D&amp;TOPIC_ID=130800" target="_blank">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron</a>.</p></div>
</div>
</div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F56430231"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiviral Agent</span>;</li>
<li>
<span class="list-set-name">Monoclonal Antibody</span></li></ul></div>
<div class="block don drugH1Div" id="F56427395"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing is based on pharmacokinetic modeling and simulation; the youngest patient in pediatric clinical trials was 10 months of age and weighed 8.6 kg. Consider local prevalence of SARS-CoV-2 variants when evaluating prophylaxis/treatment options; bamlanivimab and etesevimab are not authorized for use in geographic regions where infection or exposure are likely to be due to a nonsusceptible variant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022'])">Ref</a></span>). Further information on variants may be found at: <a href="/external-redirect?target_url=https%3A%2F%2Fcovid.cdc.gov%2Fcovid-data-tracker%2F%23variant-proportions&amp;token=DviBTzQNV61nIfudo5ZW%2F94ZVcLUx8TzUmrsLth4JU8RfSWcSDATQiYzDP63SgbrqwYUg1gY7egwR3L96Rbo%2Fg%3D%3D&amp;TOPIC_ID=130800" target="_blank">https://covid.cdc.gov/covid-data-tracker/#variant-proportions</a>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, postexposure prophylaxis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Only for use in patients who are at high risk for progressing to severe COVID-19 (including hospitalization or death; refer to the FDA fact sheet for health care providers for more information on patients at high risk for progression to severe disease), who are either not fully vaccinated or not expected to mount an adequate response to SARS-CoV-2 vaccination, <b>and</b> who either meet the CDC's criteria for close contact with an individual infected with SARS-CoV-2 or are at high risk of exposure to an individual infected with SARS-CoV-2 in an institutional setting (eg, nursing home, prison).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates weighing ≥1 kg: IV: Bamlanivimab 12 mg/kg and etesevimab 24 mg/kg administered together once as a single infusion; administer as soon as possible following exposure to SARS-CoV-2.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, mild to moderate; treatment</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022'])">Ref</a></span>): <b>Note:</b> The combination of bamlanivimab and etesevimab is only for use in patients with positive SARS-CoV-2 direct viral testing who are at high risk for progression to severe disease or hospitalization; refer to the FDA fact sheet for health care providers for more information on patients at high risk for progression to severe disease.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates weighing ≥1 kg: IV: Bamlanivimab 12 mg/kg and etesevimab 24 mg/kg administered together once as a single infusion; administer as soon as possible after a positive SARS-CoV-2 test and within 10 days of symptom onset.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> IV: No dosage adjustment recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F55482144"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consider local prevalence of SARS-CoV-2 variants when evaluating prophylaxis/treatment options; bamlanivimab and etesevimab are not authorized for use in geographic regions where infection or exposure are likely to be due to a non-susceptible variant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022'])">Ref</a></span>). Further information on variants may be found at: <a href="/external-redirect?target_url=https%3A%2F%2Fcovid.cdc.gov%2Fcovid-data-tracker%2F%23variant-proportions&amp;token=DviBTzQNV61nIfudo5ZW%2F94ZVcLUx8TzUmrsLth4JU8RfSWcSDATQiYzDP63SgbrqwYUg1gY7egwR3L96Rbo%2Fg%3D%3D&amp;TOPIC_ID=130800" target="_blank">https://covid.cdc.gov/covid-data-tracker/#variant-proportions</a>. Dosing for patients ≤12 kg is based on pharmacokinetic modeling and simulation; the youngest patient in pediatric clinical trials was 10 months of age and weighed 8.6 kg.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2221df56-383e-4fe4-9231-188c04cf91ce">COVID-19, postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, postexposure prophylaxis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Only for use in patients who are at high risk for progressing to severe COVID-19 (including hospitalization or death; refer to the FDA fact sheet for health care providers for more information on patients at high risk for progression to severe disease), who are either not fully vaccinated or not expected to mount an adequate response to SARS-CoV-2 vaccination, <b>and</b> who either meet the CDC's criteria for close contact with an individual infected with SARS-CoV-2 or are at high risk of exposure to an individual infected with SARS-CoV-2 in an institutional setting (eg, nursing home, prison).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: <b>Note: </b>Administer as soon as possible following exposure to SARS-CoV-2.</p>
<p style="text-indent:-2em;margin-left:6em;">1 to 12 kg: IV: Bamlanivimab 12 <b>mg/kg</b> and etesevimab 24<b> mg/kg</b> administered together once as a single infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;12 to 20 kg: IV: Bamlanivimab 175 mg and etesevimab 350 mg administered together once as a single infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;20 to &lt;40 kg: IV: Bamlanivimab 350 mg and etesevimab 700 mg administered together once as a single infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">≥40 kg: IV: Bamlanivimab 700 mg and etesevimab 1,400 mg administered together once as a single infusion.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bd039419-3dc9-408e-9987-a336010fc3a2">COVID-19, mild to moderate; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, mild to moderate; treatment</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Only for use in patients with positive SARS-CoV-2 direct viral testing who are at high risk for progression to severe disease or hospitalization; refer to the FDA fact sheet for health care providers for more information on patients at high risk for progression to severe disease.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: <b>Note</b>: Administer as soon as possible after a positive SARS-CoV-2 test and within 10 days of symptom onset.</p>
<p style="text-indent:-2em;margin-left:6em;">1 to 12 kg: IV: Bamlanivimab 12 <b>mg/kg</b> and etesevimab 24 <b>mg/kg</b> administered together once as a single infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;12 to 20 kg: IV: Bamlanivimab 175 mg and etesevimab 350 mg administered together once as a single infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;20 to &lt;40 kg: IV: Bamlanivimab 350 mg and etesevimab 700 mg administered together once as a single infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">≥40 kg: IV: Bamlanivimab 700 mg and etesevimab 1,400 mg administered together once as a single infusion.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F55482145"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Infants, Children, and Adolescents: IV: No dosage adjustment recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F55482146"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022'])">Ref</a></span>): IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild hepatic impairment: No dosage adjustment recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe hepatic impairment: There are no dosage adjustments provided in the fact sheet for health care providers (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F55487537"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="130799" href="/d/html/130799.html" rel="external">see "Bamlanivimab and etesevimab (United States: Authorization withdrawn): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2221df56-383e-4fe4-9231-188c04cf91ce">COVID-19, postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, postexposure prophylaxis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients with SARS-CoV-2 exposure, or at high risk for exposure, who are not fully vaccinated or are not expected to mount an adequate immune response to complete vaccination and are at high risk for progression to severe disease or hospitalization. Refer to the <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F145802%2Fdownload&amp;token=8RYIFfyLhIBYEqeX7m6uPPIcmd%2BjegGoPPgMvzukYB5Gr36CINrEJrWQ34bqWiwlssqAEFdyRovVvRwV6VgAwg%3D%3D&amp;TOPIC_ID=130800" target="_blank">FDA fact sheet for health care providers</a> for more information on patients at high risk for progression to severe disease. Use is not authorized for preexposure prophylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>Bamlanivimab 700 mg and etesevimab 1.4 g as a single dose (administered together as a single IV infusion); administer as soon as possible following exposure to SARS-CoV-2. <b>Note:</b> Consider local prevalence of SARS-CoV-2 variants when evaluating postexposure prophylaxis options (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bd039419-3dc9-408e-9987-a336010fc3a2">COVID-19, mild to moderate; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, mild to moderate; treatment (off-label use): Note:</b> Reserve for patients with positive SARS-CoV-2 direct viral testing who are at high risk for progression to severe disease or hospitalization; refer to the FDA fact sheet for health care providers for more information on patients at high risk for progression to severe disease. Use is <b>not</b> authorized for patients who are hospitalized due to COVID-19 or require new or increased oxygen therapy and/or respiratory support due to COVID-19 outside of a clinical trial; outcomes may be worse if used in patients requiring high-flow oxygen or mechanical ventilation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022','lexi-content-ref-Bhimraj.2021','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022','lexi-content-ref-Bhimraj.2021','lexi-content-ref-NIH.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Bamlanivimab 700 mg and etesevimab 1.4 g as a single dose (administered together as a single IV infusion); administer as soon as possible after a positive SARS-CoV-2 test and within 10 days of symptom onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022','lexi-content-ref-33475701','lexi-content-ref-Bhimraj.2021','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022','lexi-content-ref-33475701','lexi-content-ref-Bhimraj.2021','lexi-content-ref-NIH.1'])">Ref</a></span>). <b>Note: </b>Consider local prevalence of SARS-CoV-2 variants when evaluating treatment options (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022','lexi-content-ref-Bhimraj.2021','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022','lexi-content-ref-Bhimraj.2021','lexi-content-ref-NIH.1'])">Ref</a></span>). Further information may be found at: <a href="/external-redirect?target_url=https%3A%2F%2Fcovid.cdc.gov%2Fcovid-data-tracker%2F%23variant-proportions&amp;token=DviBTzQNV61nIfudo5ZW%2F94ZVcLUx8TzUmrsLth4JU8RfSWcSDATQiYzDP63SgbrqwYUg1gY7egwR3L96Rbo%2Fg%3D%3D&amp;TOPIC_ID=130800" target="_blank">https://covid.cdc.gov/covid-data-tracker/#variant-proportions</a>.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F55487539"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F55487540"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment: No dosage adjustment recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate or severe impairment: There are no dosage adjustments provided (has not been studied) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F55493673"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity and infusion related reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersensitivity reactions</b>, including <b>anaphylaxis</b> and <b>infusion related reaction,</b> have been reported with bamlanivimab and etesevimab. Patients may experience altered mental status, angioedema, asthenia, bronchospasm, cardiac arrhythmia (including atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, chills, diaphoresis, dizziness, dyspnea, fatigue, <b>fever</b>, headache, hypertension, hypotension, myalgia, nausea, <b>pruritus</b>, rash (including urticaria), reduced oxygen saturation, and throat irritation with infusion related reactions, but most reactions were mild in severity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33475701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33475701'])">Ref</a></span>). Slower infusion rates may be considered. All reactions were reversible; severe reactions required discontinuation and treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Onset: Rapid; most infusion related reactions occurred during infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33475701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33475701'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F55493672"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">The following adverse reactions and incidences are derived from the FDA-issued emergency use authorization (EUA), unless otherwise specified. Refer to EUA for information regarding reporting adverse reactions (FDA 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Miscellaneous: Infusion related reaction (1%: including severe infusion related reaction)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction (including type 1 hypersensitivity reaction, flushing, facial swelling, rash at injection site, skin rash)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (Gottlieb 2021)</p></div>
<div class="block coi drugH1Div" id="F55487528"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the FDA emergency use authorization (EUA) fact sheet for health care providers.</p></div>
<div class="block war drugH1Div" id="F55487529"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Antiviral resistance: Development of SARS-CoV-2 variants with reduced susceptibility to bamlanivimab and etesevimab may increase risk of treatment failure; consider local prevalence of SARS-CoV-2 variants when evaluating treatment options (FDA 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Clinical worsening: Clinical worsening of COVID-19, including signs or symptoms of altered mental status, arrhythmia (atrial fibrillation, bradycardia, tachycardia), fatigue, fever, hypoxia, or increased respiratory difficulty, has been reported after administration of bamlanivimab and etesevimab; some of these events required hospitalization. It is not known if these events were related to bamlanivimab and etesevimab or were due to COVID-19 progression (FDA 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Limitations of use: Bamlanivimab and etesevimab are not authorized for use in patients ≥2 years of age who are hospitalized due to COVID-19, or patients of any age who require oxygen therapy and/or respiratory support due to COVID-19, or require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 and are on chronic oxygen therapy and/or respiratory support due to underlying non–COVID-19 related comorbidity. Monoclonal antibodies, such as bamlanivimab and etesevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high-flow oxygen therapy or mechanical ventilation (FDA 2022).</p></div>
<div class="block prod-avail drugH1Div" id="F55487522"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Investigational agents; approved for emergency use authorization by the FDA February 2021.</p></div>
<div class="block foc drugH1Div" id="F55685252"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Solution, Intravenous [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Etesevimab 700 mg/20 mL (20 mL); Bamlanivimab 700 mg/20 mL (20 mL)</p></div>
<div class="block geq drugH1Div" id="F55685251"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F55724846"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Etesevimab Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">700 mg/20 mL (per mL): $0.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F55487518"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:-2em;margin-left:2em;">Bamlanivimab and etesevimab are not commercially available; they are available as part of ongoing clinical trials and under an emergency use authorization (EUA) from the FDA. The Department of Health and Human Services will determine weekly distribution amounts for each state/territory based on weekly reports of new COVID-19 cases and hospitalizations, in addition to data on inventories and use submitted to the federal government. State and territorial health departments will identify which sites in their respective jurisdictions receive product as well as the amount they will receive.</p>
<p style="text-indent:-2em;margin-left:2em;">As part of the EUA, information consistent with fact sheets pertaining to emergency use of bamlanivimab and etesevimab are required to be available for health care providers and patients/caregivers, and certain mandatory requirements for the combination's administration under the EUA must be met as outlined in the FDA EUA letter; the fact sheets and EUA letter may be accessed at https://www.covid19.lilly.com/bam-ete. Additionally, health care providers must track and report all medication errors and serious adverse events potentially associated with bamlanivimab and etesevimab use by either submitting a MedWatch form (<a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedwatch%2Freport.htm&amp;token=8RYIFfyLhIBYEqeX7m6uPNcm5lNJ%2BSfidIV4m5OTN5Ih2EApxCjHbBkH0Y1jxFob&amp;TOPIC_ID=130800" target="_blank">https://www.fda.gov/medwatch/report.htm</a>) or FDA Form 3500 (health professional) by mail or fax (1-800-FDA-0178); a copy of all MedWatch forms should also be provided to Eli Lilly and Company.</p></div>
<div class="block admp drugH1Div" id="F55482148"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Although supplied as separate products, both drugs should be prepared in a single infusion bag for administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: If infusion solution is refrigerated following preparation, allow solution to come to room temperature (~20 minutes) prior to administration. Administer as an IV infusion through a PVC or polyethylene-lined PVC infusion set containing a 0.2 or 0.22 micron in-line or add-on polyethersulfone filter.</p>
<p style="text-indent:-2em;margin-left:4em;">Rate of infusion is dependent upon patient weight and size of infusion bag:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Weight &lt;40 kg:</b> Infuse mixed, undiluted solution over ≥16 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Weight ≥40 kg:</b> Dilute prior to administration.</p>
<p style="text-indent:-2em;margin-left:8em;">Diluted in 50 mL bag: Infuse over ≥21 minutes.</p>
<p style="text-indent:-2em;margin-left:8em;">Diluted in 100 mL bag: Infuse over ≥31 minutes.</p>
<p style="text-indent:-2em;margin-left:8em;">Diluted in 150 mL bag: Infuse over ≥41 minutes.</p>
<p style="text-indent:-2em;margin-left:8em;">Diluted in 250 mL bag:</p>
<p style="text-indent:-2em;margin-left:10em;">Weight 40 to &lt;50 kg: Infuse over ≥70 minutes.</p>
<p style="text-indent:-2em;margin-left:10em;">Weight ≥50 kg: Infuse over ≥60 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Infuse the entire contents of the bag to avoid underdosage; flush line with NS following completion of infusion to ensure delivery of required dose. Slow or interrupt infusion and treat as appropriate if the patient develops any signs of infusion-associated events (eg, fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia, chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vasovagal reactions, dizziness, diaphoresis); if severe or life-threatening hypersensitivity reactions occur, immediately discontinue infusion and provide emergency care (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F55487541"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Must be diluted prior to administration. If diluted solution is refrigerated following preparation, allow solution to come to room temperature (~20 minutes) prior to administration. Administer as an IV infusion at a rate of ≤310 mL/hour (≤266 mL/hour for patients &lt;50 kg using the 250 mL prefilled NS infusion bag); infuse entire contents of the bag to avoid underdosage. Administer through a PVC or polyethylene-lined PVC infusion set containing a 0.2 or 0.22 micron in-line or add-on polyethersulfone filter. Slow or stop infusion and treat as appropriate if an infusion-related reaction occurs. Flush infusion line with NS following completion of infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2022'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F55487531"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store intact vials at 2°C to 8°C (36°F to 46°F); protect from light. Do not freeze, shake, or expose to direct light (FDA 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">Solution requires dilution prior to administration when using in patients ≥18 years of age and ≥40 kg. Diluted infusion solution should be administered immediately. If immediate administration is not possible, store diluted infusion solution for up to 24 hours refrigerated at 2°C to 8°C (36°F to 46°F) or up to 7 hours at 20°C to 25°C (68°F to 77°F) including infusion time. If refrigerated, allow infusion solution to warm to room temperature for ~20 minutes prior to administration (FDA 2022).</p></div>
<div class="block usep drugH1Div" id="F55482140"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Treatment: </i>Investigational agent for the treatment of mild to moderate COVID-19 in patients with positive SARS-CoV-2 direct viral testing who are at high risk for progressing to severe COVID-19, including hospitalization or death (FDA issued emergency use authorization [EUA] in all ages).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Postexposure prophylaxis: </i>Investigational agent for postexposure prophylaxis of COVID-19 in patients who are at high risk for progressing to severe COVID-19 (including hospitalization or death), who are either not fully vaccinated or not expected to mount an adequate response to SARS-CoV-2 vaccination, <b>and</b> who either meet the CDC's criteria for close contact with an individual infected with SARS-CoV-2 or are at high risk of exposure to an individual infected with SARS-CoV-2 in an institutional setting (ie, nursing home, prison) (FDA issued EUA in all ages).</p>
<p style="text-indent:-2em;margin-left:2em;">Per the EUA, the following, in addition to other potential factors (eg, race, ethnicity), may place patients at higher risk for progressing to severe COVID-19 (FDA 2022):</p>
<p style="text-indent:-2em;margin-left:4em;">• Age &lt;1 year</p>
<p style="text-indent:-2em;margin-left:4em;">• Older age (eg, ≥65 years)</p>
<p style="text-indent:-2em;margin-left:4em;">• Overweight or obesity</p>
<p style="text-indent:-2em;margin-left:4em;">• Pregnancy</p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic kidney disease</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression (due to treatment or underlying disease)</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease (including congenital heart disease) or hypertension</p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic lung diseases (eg, chronic obstructive pulmonary disease, moderate to severe asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension)</p>
<p style="text-indent:-2em;margin-left:4em;">• Sickle cell disease</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurodevelopmental disorders (eg, cerebral palsy) or other conditions that confer medical complexity (eg, genetic or metabolic syndromes, severe congenital anomalies)</p>
<p style="text-indent:-2em;margin-left:4em;">• Medical technology dependence (eg, tracheostomy, gastrostomy, positive pressure ventilation [not related to COVID-19])</p>
<p style="text-indent:-2em;margin-left:2em;">Bamlanivimab and etesevimab are NOT authorized for use in patients ≥2 years of age who are hospitalized due to COVID-19, for patients of any age who require new or increased oxygen therapy or respiratory support due to COVID-19, or for use in geographic regions where infection or exposure are likely to be due to a nonsusceptible variant (FDA 2022).</p></div>
<div class="block mst drugH1Div" id="F55487516"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Bamlanivimab may be confused with belimumab.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F55504378"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F55504375"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F55487525"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Bamlanivimab and etesevimab (administered in combination) is under FDA emergency use authorization (EUA) for the treatment and postexposure prophylaxis of COVID-19 (FDA 2022). The original clinical trials required male and female patients of reproductive potential to use effective contraception during the study (Gottlieb 2021).</p></div>
<div class="block pri drugH1Div" id="F55487526"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">The use of bamlanivimab in combination with etesevimab is under FDA emergency use authorization (EUA) for the treatment and postexposure prophylaxis of COVID-19. Nonclinical reproductive toxicity studies have not been conducted (FDA 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Bamlanivimab and etesevimab are humanized monoclonal antibodies (IgG<sub>1</sub>). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of bamlanivimab in combination with etesevimab during pregnancy are limited (Crispino 2023; McCreary 2022; Richley 2022). The original clinical trials of bamlanivimab in combination with etesevimab did not include pregnant patients (Gottlieb 2021). The potential benefits or risks of in utero exposure to bamlanivimab and etesevimab to the fetus are not known (FDA 2022).</p>
<p style="text-indent:0em;margin-top:2em;">The risk of severe morbidity and mortality from COVID-19 infection is increased in symptomatic pregnant patients compared to nonpregnant patients. Pregnant and recently pregnant patients with moderate or severe infection are at increased risk of complications such as hypertensive disorders of pregnancy, postpartum hemorrhage, or other infections compared to pregnant patients without COVID. Symptomatic pregnant patients may require ICU admission, mechanical ventilation, or ventilatory support (ECMO). Other adverse pregnancy outcomes include preterm birth and stillbirth. The risk of coagulopathy, cesarean delivery, and maternal death may be increased; neonates have an increased risk for NICU admission. Maternal age and comorbidities such as diabetes, hypertension, lung disease, and obesity may also increase the risk of severe illness in pregnant and recently pregnant patients (ACOG 2023; NIH 2022).</p>
<p style="text-indent:0em;margin-top:2em;">In general, the treatment of COVID-19 infection during pregnancy is the same as in nonpregnant patients. However, because data for most therapeutic agents in pregnant patients are limited, treatment options should be evaluated as part of a shared decision-making process (NIH 2022). Pregnancy is one of the medical conditions listed in the EUA eligibility criteria for bamlanivimab in combination with etesevimab. According to the EUA, dose adjustments are not recommended for patients who are pregnant (FDA 2022). Information related to the treatment of COVID-19 during pregnancy continues to emerge; refer to current guidelines for the treatment of pregnant patients.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor maternal and infant outcomes following exposure to COVID-19 during pregnancy is ongoing. Health care providers are encouraged to enroll patients exposed to COVID-19 during pregnancy in the Organization of Teratology Information Specialists pregnancy registry (1-877-311-8972; https://mothertobaby.org/join-study/).</p></div>
<div class="block mopp drugH1Div" id="F55482149"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for infusion-related reactions (eg, fever, chills, hypotension, rash, pruritus) and hypersensitivity/anaphylaxis during infusion and for 1 hour following infusion completion (FDA 2022).</p></div>
<div class="block pha drugH1Div" id="F55487557"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Bamlanivimab and etesevimab are both recombinant neutralizing human IgG1k monoclonal antibodies to the spike protein of SARS-CoV-2. They bind to different, but overlapping receptors, thus blocking the spike protein attachment to the human ACE2 receptor. Use of the combination is expected to reduce the risk of viral resistance (FDA 2022).</p></div>
<div class="block phk drugH1Div" id="F55487532"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">C<sub>max</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Bamlanivimab (700 mg): 196 mg/L.</p>
<p style="text-indent:-2em;margin-left:6em;">Etesevimab (1.4 g): 504 mg/L.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Bamlanivimab: 2.87 L (central); 2.71 L (peripheral).</p>
<p style="text-indent:-2em;margin-left:6em;">Etesevimab: 2.38 L (central); 1.98 L (peripheral).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Bamlanivimab and etesevimab are expected to be degraded into small peptides and component amino acids via catabolic pathways in the same manner as endogenous IgG antibodies.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Bamlanivimab: 17.6 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Etesevimab: 25.1 days.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-ACOG.2020">
<a name="ACOG.2020"></a>American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for obstetricians-gynecologists, obstetrics. https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics. Accessed December 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bamlanivimab-and-etesevimab-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bhimraj.2021">
<a name="Bhimraj.2021"></a>Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America (IDSA) guidelines on the treatment and management of patients with COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Updated September 15, 2021. Accessed September 15, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bamlanivimab-and-etesevimab-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34081073">
<a name="34081073"></a>Cohen MS, Nirula A, Mulligan MJ, et al; BLAZE-2 Investigators. Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial. <i>JAMA</i>. 2021;326(1):46-55. doi:10.1001/jama.2021.8828<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bamlanivimab-and-etesevimab-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/34081073/pubmed" id="34081073" target="_blank">34081073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37630512">
<a name="37630512"></a>Crispino P, Marocco R, Di Trento D, et al. Use of monoclonal antibodies in pregnant women infected by COVID-19: a case series. <i>Microorganisms</i>. 2023;11(8):1953. doi:10.3390/microorganisms11081953<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bamlanivimab-and-etesevimab-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/37630512/pubmed" id="37630512" target="_blank">37630512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33475701">
<a name="33475701"></a>Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. <i>JAMA</i>. 2021;325(7):632-644. doi:10.1001/jama.2021.0202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bamlanivimab-and-etesevimab-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/33475701/pubmed" id="33475701" target="_blank">33475701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36375150">
<a name="36375150"></a>McCreary EK, Lemon L, Megli C, Oakes A, Seymour CW; UPMC Magee Monoclonal Antibody Treatment Group. Monoclonal antibodies for treatment of SARS-CoV-2 infection during pregnancy: a cohort study. <i>Ann Intern Med</i>. 2022;175(12):1707-1715. doi:10.7326/M22-1329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bamlanivimab-and-etesevimab-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/36375150/pubmed" id="36375150" target="_blank">36375150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. <a href="https://www.covid19treatmentguidelines.nih.gov/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/</a>. Updated October 19, 2021. Accessed October 22, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.2021">
<a name="NIH.2021"></a>National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. <a href="https://www.covid19treatmentguidelines.nih.gov/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/</a>. Updated February 24, 2022. Accessed February 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev</i>
<i>Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bamlanivimab-and-etesevimab-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bamlanivimab-and-etesevimab-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35115451">
<a name="35115451"></a>Richley M, Rao RR, Afshar Y, et al. Neutralizing monoclonal antibodies for coronavirus disease 2019 (COVID-19) in pregnancy: a case series. <i>Obstet Gynecol</i>. 2022;139(3):368-372. doi:10.1097/AOG.0000000000004689<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bamlanivimab-and-etesevimab-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/35115451/pubmed" id="35115451" target="_blank">35115451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2021">
<a name="FDA.2021"></a>US Food and Drug Administration (FDA). Fact sheet for healthcare providers emergency use authorization (EUA) of bamlanivimab and etesevimab. <a href="https://www.fda.gov/media/145808/download" target="_blank">https://www.fda.gov/media/145808/download</a>. Published December 3, 2021. Accessed December 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2022">
<a name="FDA.2022"></a>US Food and Drug Administration (FDA). Fact sheet for healthcare providers emergency use authorization (EUA) of bamlanivimab and etesevimab. <a href="https://www.fda.gov/media/145808/download" target="_blank">https://www.fda.gov/media/145808/download</a>. Published January 24, 2022. Accessed January 31, 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 130800 Version 60.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
